Gene Study for Prostate Cancer

Precision-Based Genomics in Prostate Cancer

Recruiting Observational Study
Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 120
Sex
Male
Study type
Observational
Participants needed
2,000 (estimated)
Sponsor
National Cancer Institute (NCI) · NIH
Who this trial is looking for

This trial is looking for adult men with prostate cancer who have specific gene mutations or a strong positive response to treatment. Participants will provide health information over the phone and may give blood or urine samples for gene research.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am a man aged 18 or older
  • I have been diagnosed with prostate cancer
  • I have specific gene mutations related to my cancer
  • I have had a strong positive response to treatment

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand h…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA: * Subjects with histologically confirmed prostate cancer. * Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, CDK12, and/or MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM and/or TMB-high(\[def…
Contacts

Katherine O Lee-Wisdom, R.N.

(240) 858-3525

katherine.lee-wisdom@nih.gov

CONTACT

Fatima H Karzai, M.D.

(301) 480-7174

fatima.karzai@nih.gov

CONTACT